Vaxil Bio Ltd.
VXLLF
$0.008
$0.00233.33%
| 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | 09/30/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 39.60K | 45.30K | 28.20K | -39.00K | 23.90K |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 41.80K | 35.80K | 43.00K | -22.80K | 24.60K |
| Operating Income | -41.80K | -35.80K | -43.00K | 22.80K | -24.60K |
| Income Before Tax | -35.90K | -35.80K | -43.00K | 19.10K | -20.90K |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -35.90K | -35.80K | -43.00K | 19.10K | -20.90K |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -35.90K | -35.80K | -43.00K | 19.10K | -20.90K |
| EBIT | -41.80K | -35.80K | -43.00K | 22.80K | -24.60K |
| EBITDA | -- | -- | -- | 23.20K | -24.20K |
| EPS Basic | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Basic EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Normalized Diluted EPS | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Average Basic Shares Outstanding | 136.98M | 136.98M | 136.98M | 136.98M | 136.98M |
| Average Diluted Shares Outstanding | 136.98M | 136.98M | 136.98M | 136.98M | 136.98M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
